The Cicor Group announced that it has signed a Memorandum of Understanding with Clayens Group for a strategic collaboration to create global one-stop CDMO solutions for demanding applications in medical and industrial markets with a focus on smart drug delivery devices. This strategic partnership enables both companies to offer a one-stop shop for customized, integrated technology solutions that are unmatched in innovation, quality and efficiency, from concept to market, regardless of complexity. Customers, particularly in the medical technology and industrial markets, will benefit from the combination of Cicor's and Clayens' complementary skills and technologies.

The joint offering specifically responds to the growing demand for smart drug delivery devices that significantly improve patient care, enable traceability of high value medicine and ultimately reduce healthcare cost. While developing a joint offering entirely focused on new programs, both companies will remain independent of each other and work at arms-length. The collaboration of Cicor and Clayens as independent groups is endorsed by One Equity Partners (OEP), a shareholder in both companies.

Cicor is committed to leveraging this strategic collaboration to drive innovation and create value for all stakeholders, reinforcing its commitment to excellence in the EMS and plastics industries.